Get the Stockscreener App
2.29
7.29%
-0.18
After Hours:
2.28
-0.01
-0.44%
Gain Therapeutics Inc Stock (GANX) Latest News
Best Momentum Stocks to Buy for January 9th - MSN
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) to Release Quarterly Earnings on Tuesday - Defense World
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 24.5% - Defense World
Scotiabank Initiates Coverage of Gain Therapeutics (GANX) with Sector Outperform Recommendation - MSN
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease - IT Business Net
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - openPR
Gain Therapeutics Doses First Participant In Phase 1b Trial Of GT-02287 For Parkinson's Disease - Nasdaq
Gain Therapeutics Begins Dosing Parkinson's Patients in GT-02287 Study -March 14, 2025 at 08:29 am EDT - Marketscreener.com
Gain Therapeutics Initiates Dosing in Phase 1b Clinical Trial for Parkinson's Disease Treatment GT-02287 - Nasdaq
Promising Parkinson's Treatment Enters Next Phase: Gain's GT-02287 Shows 50% Target Engagement - StockTitan
Jones Financial Companies Lllp Purchases 44,750 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Seres Therapeutics, Inc. SEC 10-K Report - TradingView
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo
Closing Figures Unveiled: Dave Inc (DAVE) Gain 0.18, Closes at 83.36 - The Dwinnex
Gain Therapeutics (NASDAQ:GANX) Research Coverage Started at Scotiabank - Defense World
Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - EquityPandit
Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) PT at $8.20 - Defense World
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - MSN
Scotiabank starts Gain Therapeutics stock with $12 target - Investing.com
Scotiabank starts Gain Therapeutics stock with $12 target By Investing.com - Investing.com UK
Gain Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - The Manila Times
Gain Therapeutics, Inc. to Present Clinical Stage Drug Candidate GT-02287 at AD/PD™ 2025 Conference in Vienna - Nasdaq
Can This New Drug Candidate Transform Parkinson's Disease Treatment? Key Data Coming - StockTitan
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain - Yahoo Finance
Top Trend In Retinal Vein Occlusion Market 2025: Pioneering Innovations In The Retinal Vein Occlusion Marke... - WhaTech
OPKO HEALTH, INC. SEC 10-K Report - TradingView
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Finance
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales - MSN
GAIN THERAPEUTICS: A Microcap Stock to Love - substack.com
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
MSSM's Underlying Holdings Imply 19% Gain Potential - Nasdaq
Investing in Neurizon Therapeutics (ASX:NUZ) five years ago would have delivered you a 54% gain - Yahoo Finance
Does Gain Therapeutics Inc (NASDAQ: GANX) Still Need To Convince Analysts? - Stocks Register
2025 Pipeline Report: The Edge of Greatness? - Pharmaceutical Executive
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Travere Therapeutics Delivers Over 180% Gain In 6 Months - Nasdaq
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Benzinga
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
Daily Progress: Wearable Devices Ltd (WLDS) Gain 1.76, Closing at 0.95 - The Dwinnex
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research - The Globe and Mail
Janux Therapeutics Inc (NASDAQ: JANX) Gain Of 80.16% Compared To 52-Week Low; YTD Fall -26.47% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
reAlpha Tech Corp (NASDAQ: AIRE) Gain Of 70.56% Compared To 52-Week Low; YTD Fall -37.72% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Sacks Parente Golf Inc (NASDAQ: SPGC): Can The Stock Still Lose Despite An 38.15% YTD Gain? - Marketing Sentinel
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials - TipRanks
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - citybiz
Travere Therapeutics Inc (TVTX) deserves deeper analysis - US Post News
Can you now get a good deal on PTC Therapeutics Inc’s shares? - US Post News
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Philip Morris Q4: Earnings Beat, Smoke-Free Sales Gain Ground & More - Yahoo Finance
Gain Therapeutics, Inc. Provides 2025 Outlook and Progress Update on GT-02287 for Parkinson’s Disease - Nasdaq
Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching - StockTitan
0.22%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):